Profile data is unavailable for this security.
About the company
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
- Revenue in CHF (TTM)94.64m
- Net income in CHF1.12m
- Incorporated--
- Employees325.00
- LocationCosmo Pharmaceuticals NVRiverside II, Sir John Rogerson's QuayDUBLIN IrelandIRL
- Phone+353 18170370
- Websitehttps://www.cosmopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kuros Biosciences AG | 33.56m | -13.73m | 254.01m | 80.00 | -- | 4.47 | -- | 7.57 | -0.3697 | -0.3697 | 0.9175 | 1.54 | 0.4347 | 2.40 | 7.27 | 419,550.00 | -17.78 | -13.47 | -21.34 | -14.84 | 71.31 | 78.73 | -40.90 | -81.48 | 1.69 | -84.04 | 0.0364 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Idorsia Ltd | 184.69m | -374.06m | 328.97m | 1.36k | -- | -- | -- | 1.78 | -2.11 | -2.11 | 1.04 | -4.65 | 0.2201 | 0.2374 | 62.89 | 135,698.00 | -44.59 | -43.40 | -62.30 | -48.06 | 94.92 | -- | -202.54 | -966.50 | 1.02 | -26.39 | 3.77 | -- | 174.70 | -9.29 | -30.46 | -- | 28.72 | -- |
| Basilea Pharmaceutica AG Allschwil | 157.63m | 10.45m | 527.33m | 147.00 | 45.92 | -- | 43.76 | 3.35 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Polypeptide Group AG | 317.86m | -50.33m | 955.48m | 1.20k | -- | 2.55 | -- | 3.01 | -1.52 | -1.52 | 9.60 | 11.31 | 0.5137 | 2.31 | 5.08 | 264,446.60 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| Cosmo Pharmaceuticals NV | 94.64m | 1.12m | 1.26bn | 325.00 | 1,034.42 | 2.77 | 82.80 | 13.36 | 0.0697 | 0.0697 | 5.87 | 26.01 | 0.1473 | 3.06 | 2.88 | 291,207.20 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| BB BIOTECH AG | 674.00k | -206.61m | 2.25bn | -- | -- | 0.9573 | -- | 3,333.04 | -3.76 | -3.76 | 0.0122 | 42.36 | 0.0002 | -- | -- | -- | -7.26 | 2.34 | -8.25 | 2.52 | -760.83 | 99.06 | -30,653.86 | 35.40 | -- | -0.2385 | 0.116 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
| Dottikon ES Holding AG | 338.23m | 86.17m | 3.21bn | 694.00 | 36.71 | 3.75 | 29.89 | 9.48 | 6.24 | 6.24 | 24.49 | 61.10 | 0.3135 | 0.6339 | 5.39 | 498,861.30 | 7.99 | 7.48 | 9.58 | 8.48 | 67.58 | 78.94 | 25.48 | 22.35 | 1.65 | 101.25 | 0.1062 | -- | 26.80 | 15.09 | 47.94 | 27.70 | 30.78 | -- |
| Siegfried Holding AG | 1.27bn | 112.06m | 3.93bn | 3.93k | 33.11 | 4.41 | 20.23 | 3.09 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
| BACHEM HOLDING AG | 577.32m | 111.86m | 5.99bn | 2.01k | 53.29 | 4.54 | 38.15 | 10.38 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 16 Aug 2023 | 524.55k | 2.99% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 347.55k | 1.98% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 141.78k | 0.81% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 119.04k | 0.68% |
| Z�rcher Kantonalbank (Investment Management)as of 29 Feb 2024 | 111.38k | 0.64% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 111.14k | 0.63% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 105.11k | 0.60% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 62.58k | 0.36% |
| Healthinvest Partners ABas of 30 Jun 2022 | 60.00k | 0.34% |
| 3V Asset Management AGas of 28 Mar 2024 | 41.66k | 0.24% |
